LinkMed logo
sp
sp divider
The LinkMed portfolio consists of a number of life science companies, several of which are nearing the commercialization phase, while others are already selling their products or services. Between them, these companies account for more than 50 different projects in a wide range of therapeutic areas – from HIV and cancer to eye disease and allergies.
COMPANIES IN SEVERAL SECTORS
LinkMed has created a portfolio of twelve companies, four in drug development and biotechnology and eight in diagnostics and medical technology
MANY COMPANIES, LOWER RISKS
By investing in several companies, we spread risks and reduce our exposure to the development in individual projects. Our goal is to continually develop and manage between 15 and 20 portfolio companies. Therefore, we plan to invest in several new companies in the coming years.
Likvor

Likvor AB

Operations: Likvor has developed a diagnostic instrument to measure cerebrospinal fluid pressure (CSF). Today, healthcare professionals have difficulties diagnosing patients who, in combination minor CSF pressure changes, show symptoms of disease such as disturbances in balance, urinary incontinence and dementia, a condition called Normal Pressure Hydrocephalus (NPH). Implanting a shunt into the brain can help patients return to their normal lives. The instrument can also be used to assess the functionality of a patient’s shunt.

Sektor: Diagnostics and medical technology

Therapeutic area: Neurology / diagnostics

CEO: Kjell Öberg

Chairman: Jan Olsson

Venture manager: Okee Williams

Ownership stake: 49.0%

Address: Likvor AB
Uminova Invest
Box 7970
SE-907 19 Umeå
Sweden

www.likvor.com

Back